Fang D Z, Liu B W
Department of Biochemistry, West China University of Medical Sciences, Chengdu Sichuan, People's Republic of China.
Mol Cell Biochem. 2000 Apr;207(1-2):57-64. doi: 10.1023/a:1007038129481.
Apo C-III plays an important role in the metabolism of plasma triglyceride, which can delay the catabolism of triglyceride-rich lipoproteins by interfering with apo E-mediated receptor clearance of remnant particles from plasma. The mechanism of the interference has not yet been defined. To further explore the role of apo C-III, we first injected mice with 125I-apo C-III. The measurement of radioactivity showed that liver took up 3.3-10 fold as much radioactivity as other organs such as heart, spleen, lung, kidney, stomach, large intestine, small intestine, and muscle. This was confirmed by incubating the tissue homogenates of the organs with 125I-apo C-III that the radiolabeled apo C-III specifically bound to only hepatic homogenate. To investigate which subcellular part or parts of hepatic cells play the role of binding to apo C-III, hepatic cell components of nucleus, mitochondria, microsomes and plasma membranes were then incubated with 125I-apo C-III. The radiolabeled apo C-III could specifically bind to only hepatic plasma membranes. Finally hepatic plasma membranes were purified to study the characteristics of the specific binding with apo C-III. Addition of increasing concentration of 125I-apo C-III to human hepatic plasma membranes revealed saturable binding to membranes with a Kd of 0.31 +/- 0.07 micromol/l. The maximum specific binding capacity was 1.74 +/- 0.45 microg apo C-III/mg membrane protein. In competition studies using unlabeled apo C-III and isolated lipoproteins HDL, LDL and VLDL, only apo C-III and VLDL effectively competed with 125I-apo C-III for membrane binding. The binding of 125I-apo C-III to human liver plasma membranes was Ca2+-independent, and was abolished when plasma membranes were treated with trypsin. The characteristics of 125I-apo C-III binding to mouse liver plasma membranes were similar to those of human liver plasma membranes with the exception of a binding maximum of 1.52 +/- 0.39 microg apo C-III/mg membrane protein. We conclude that apo C-III exhibits high-affinity binding to hepatic plasma membranes, which is saturable, reverse and specific.
载脂蛋白C-III在血浆甘油三酯代谢中起重要作用,它可通过干扰载脂蛋白E介导的残余颗粒从血浆中的受体清除来延缓富含甘油三酯脂蛋白的分解代谢。这种干扰机制尚未明确。为进一步探究载脂蛋白C-III的作用,我们首先给小鼠注射了125I-载脂蛋白C-III。放射性测量显示,肝脏摄取的放射性是心脏、脾脏、肺、肾脏、胃、大肠、小肠和肌肉等其他器官的3.3至10倍。用125I-载脂蛋白C-III孵育这些器官的组织匀浆证实,放射性标记的载脂蛋白C-III仅特异性结合肝匀浆。为研究肝细胞的哪些亚细胞部分在与载脂蛋白C-III结合中起作用,随后将细胞核、线粒体、微粒体和质膜的肝细胞成分与125I-载脂蛋白C-III一起孵育。放射性标记的载脂蛋白C-III仅能特异性结合肝质膜。最后纯化肝质膜以研究与载脂蛋白C-III特异性结合的特性。向人肝质膜中加入浓度递增的125I-载脂蛋白C-III显示,与膜的结合具有饱和性,解离常数(Kd)为0.31±0.07微摩尔/升。最大特异性结合容量为1.74±0.45微克载脂蛋白C-III/毫克膜蛋白。在使用未标记的载脂蛋白C-III以及分离的脂蛋白高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和极低密度脂蛋白(VLDL)的竞争研究中,只有载脂蛋白C-III和VLDL能有效与125I-载脂蛋白C-III竞争膜结合。125I-载脂蛋白C-III与人肝质膜的结合不依赖Ca2+,且当质膜用胰蛋白酶处理时结合被消除。125I-载脂蛋白C-III与小鼠肝质膜结合特性与人肝质膜相似,只是最大结合量为1.52±0.39微克载脂蛋白C-III/毫克膜蛋白。我们得出结论,载脂蛋白C-III与肝质膜表现出高亲和力结合,这种结合具有饱和性、可逆性和特异性。